Sugi Predict

Sugi Predict / Compounds / SCHEMBL171825

SCHEMBL171825

SCHEMBL171825

Cc1ccc(N)cc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.61
▸ GAA P10253 2/20 0.61
▸ GLA P06280 1/20 0.61
▸ POLB P06746 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.52
▸ CASP1 P29466 4/20 0.50
▸ CYP3A4 P08684 2/20 0.46
▸ NR1H2 P55055 1/20 0.44
▸ KIF11 P52732 1/20 0.42
▸ PDE10A Q9Y233 1/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ AR P10275 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ SRC P12931 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766284 1.00 TSHR (0.61) TSHRGAAGLAPOLBALDH1A1
SCHEMBL20971955 0.85 TSHR (0.55) TSHRGAAGLAPOLBALDH1A1
SCHEMBL12024599 0.84 ALDH1A1 (0.50) TSHRGAAGLAPOLBALDH1A1
Tert-Butyl Formate SCHEMBL28075418 0.84 TSHR (0.46) TSHRGAAGLAPOLBALDH1A1
SCHEMBL2059016 0.82 TSHR (0.56) TSHRGAAGLAPOLBALDH1A1
SCHEMBL30750882 0.82 TSHR (0.56) TSHRGAAGLAPOLBALDH1A1
SCHEMBL10021502 0.79 GAA (0.77) TSHRGAAGLAPOLBALDH1A1
SCHEMBL14070070 0.79 ALDH1A1 (0.54) TSHRGAAGLAPOLBALDH1A1
SCHEMBL827884 0.78 TSHR (0.70) TSHRGAAGLAPOLBALDH1A1
SCHEMBL29420085 0.78 TSHR (0.70) TSHRGAAGLAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 750 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120157609-A Polynorbornene imide film and preparation method and application thereof 哈尔滨理工大学 2025-06-17 — — CN claimed
EP-4479546-A2 PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF Teva Pharmaceuticals International GmbH (CH) 2024-12-25 — — EP claimed
CN-113957106-B Avacopan and preparation method of intermediate thereof 暨明医药科技（苏州）有限公司 2024-04-19 — — CN claimed
US-11845729-B2 Processes and intermediates in the preparation of C5aR antagonists CHEMOCENTRYX, INC. (US) 2023-12-19 — — US claimed
WO-2023158722-A2 PROCESSES FOR PREPARATION OF AVACOPAN AND INTERMEDIATES THEREOF TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) 2023-08-24 — — WO claimed
US-20230008966-A1 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2023-01-12 — — US claimed
EP-3682879-B1 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2022-08-03 — — EP claimed
CN-113957106-A Preparation method of Avacopan and intermediate thereof 暨明医药科技（苏州）有限公司 2022-01-21 — — CN claimed
CN-111606923-B Synthesis method of racemic clopidogrel 武汉理工大学 2021-08-24 — — CN claimed
CN-113121415-A Processes and intermediates for preparing C5aR antagonists 凯莫森特里克斯股份有限公司 2021-07-16 — — CN claimed
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases NOVARTIS AG (CH) 2009-01-29 — — US claimed
EP-1996558-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 — — EP claimed
EP-1996578-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES Novartis AG (CH) 2008-12-03 — — EP claimed
WO-2008009487-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2008-01-24 — — WO claimed
WO-2007104538-A1 HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES NOVARTIS AG (CH) 2007-09-20 — — WO claimed
JP-2007523865-A — — 2007-08-23 — — JP claimed
US-7129235-B2 Amides useful for treating pain ABBOTT LABORATORIES (US) 2006-10-31 — — US claimed
EP-1646621-A2 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2006-04-19 — — EP claimed
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I ABBVIE INC. 2005-04-14 — — US claimed
WO-2005007642-A2 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2005-01-27 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030009-A1 Heterobicyclic Carboxamides as Inhibitors for Kinases PHKG1, MAP3K20, CDK2 TSHR 3579/4885GAA 1247/4885GLA 4100/4885
US-11845729-B2 Processes and intermediates in the preparation of C5aR antagonists C5AR1, C5AR2, C3AR1 TSHR 192/4885GAA 4738/4885GLA 2778/4885
US-20230008966-A1 PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 TSHR 192/4885GAA 4738/4885GLA 2778/4885
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I TRPV1, OPRL1, TRPV6 TSHR 397/4885GAA 2594/4885GLA 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.